TSHZ3

Across TCGA pan-cancer cohorts, TSHZ3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TSHZ3 data layer compared with 24 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher TSHZ3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TSHZ3 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

LSCC, UCEC, and PDAC are the cancer types where TSHZ3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	III,IV	0.411	0.897	.004	43	view →
UCEC	DFS	Quartile	II,III,IV	0.364	1.000	.005	40	view →
PDAC	OS	Median	All	0.830	0.350	.040	6	view →
GBM	OS	Median	All	0.725	0.875	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TSHZ3–LSCC (DFS)

Open the LSCC breakdown →